This study is testing a new way to give radiation therapy called Stereotactic Ablative Breast Radiotherapy (SABER) to women with early-stage breast cancer. The goal is to find the best dose of SABER to give before surgery, in a shorter amount of time. Researchers will be looking for the recommended dose of SABER within 13 weeks. To join, you must be a woman at least 50 years old with early-stage breast cancer that is ER/PR positive and HER2 negative. Your Oncotype or MammaPrint results are also needed. The study is currently unclear on its recruitment status and plans to enroll 18 participants.

Study design

This is an interventional study, meaning participants will receive a specific treatment. It aims to enroll 18 women.

What's involved

Participants will receive SABER radiation therapy in 5 sessions over 2 weeks, given on non-consecutive days. This will happen before standard partial mastectomy/axillary surgery.

Compensation

Not stated in the trial record.

Follow-up

The primary endpoint, finding the recommended dose, is measured up to 13 weeks.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.